HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval

HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.

AbbVie dramatically outspent its pharma company rivals in 2023 to promote its drugs to doctors

WASHINGTON — Pharmaceutical giant AbbVie paid health care providers roughly $145.7 million last year to promote its drugs, according to a STAT analysis of newly

July 5, 2024

Texas Emergency Medicine Residency Program Won’t Shut Down

A Texas emergency medicine residency program was saved from being permanently closed this month after a groundswell of support from residents, physicians, and local politicians,

December 12, 2023

Amyloid-β and tau disrupt brain activity, driving early cognitive decline in Alzheimer’s risk

Researchers discover how amyloid-β and tau pathologies interact to drive early neurophysiological changes and cognitive decline in older adults at risk of Alzheimer’s disease.

September 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.